study question: What is the role of myostatin and its relationship with obesity, androgens and follistatin levels in women with polycystic ovary syndrome (PCOS)? summary answers: The myostatin level was positively correlated to the risk of abdominal obesity, but negatively associated with circulating levels of dehydroepiandrosterone sulfate (DHEAS) and follistatin in women with PCOS.
Introduction
Polycystic ovarian syndrome (PCOS) is one of the most common endocrine diseases in women of reproductive age (DiamantiKandarakis et al., 1999) . Women with PCOS are characterized by phenotypic or biochemical hyperandrogenemia, abdominal obesity, insulin resistance (IR), increased risk of metabolic syndrome (Chen et al., 2006) and hepatic steatosis (Chen et al., 2010) . Lifestyle modification with exercise, weight reduction and dietary control to reduce the fat mass and IR, and to increase the muscle mass is the current treatment of choice for women with PCOS (Harrison et al., 2011) . However, such treatments with exercise and lifestyle modification still lead to conflicting results in women with PCOS (Thomson et al., 2008 (Thomson et al., , 2011 Harrison et al., 2011) . The heterogeneity of characteristics in women with PCOS might account for the different outcomes with such lifestyle interventions.
Myostatin is a secreted growth factor expressed in adipose tissue and skeletal muscle that negatively regulates skeletal muscle mass (Allen et al., 2008) . Overexpression of myostatin in transgenic male mice is associated with reduced muscle mass and increased fat mass (Reisz-Porszasz et al., 2003) . Myostatin knockout mice have a dramatic increase in muscle mass, a reduction in fat mass and a resistance to obesity caused by diet and genetic mutation (McPherron and Lee, 2002; Guo et al., 2009) . Because muscle is a significant glucose consumer, it is not surprising that constitutive myostatin depletion by conditional genetic mutation (Wilkes et al., 2009; Burgess et al., 2011) and application of a myostatin receptor blocker (Akpan et al., 2009) can reduce weight gain and improve hyperglycemia, IR and hepatic steatosis caused by a high-fat diet in mice.
Follistatin is known to be the most potent antagonist of myostatin (Lee and McPherron, 2001; Haidet et al., 2008) and has been reported as a candidate gene for women with PCOS (Urbanek et al., 1999) . The transgenic expression of follistatin suppresses myostatin levels and leads to an increase of the size and strength of skeletal muscle in murine models (Lee and McPherron, 2001; Haidet et al., 2008) . In addition, follistatin has been reported to be involved in the pathogenesis of adipogenesis in women (Flanagan et al., 2009) . However, there are no studies that have determined the role of myostatin and its interaction with follistatin and androgen in women with PCOS.
Hyperandrogenism of ovarian or adrenal origin is one of the most important characteristics of women with PCOS, and is involved in the morphology of polycystic ovaries and ovulatory dysfunction (Jonard and Dewailly, 2004; Carmina and Lobo, 2007; Chen et al., 2008) . Although the main source of androgens in women with PCOS is testosterone from the ovaries (Barnes et al., 1989) , 36 -50% of women with PCOS also have elevated adrenal androgens in the form of dehydroepiandrosterone sulfate (DHEAS) (Carmina and Lobo, 2007) . In contrast to the effect of total testosterone, higher circulating serum DHEAS levels have been reported to correlate with a reduced risk of abdominal obesity and favorable metabolic parameters, including better lipid profiles and a higher insulin sensitivity index in women with PCOS (Buffington et al., 1991; Brennan et al., 2009; Chen et al., 2011) ; however, the basis for such a relationship is unclear. Androgens, in the form of DHEA and testosterone supplements, increase muscle mass, muscle strength and decreased fat mass in elderly men and women (Diamond et al., 1996; Snyder et al., 1999; Kenny et al., 2010) ; however, the findings are inconsistent (Nair et al., 2006) . Further, studies regarding the relationship between androgen and myostatin are limited (McMahon et al., 2003; Mendler et al., 2007; Lakshman et al., 2009; Diel et al., 2010) .
We speculated that if the relationship between hormonal profiles and the regulation of muscle metabolism could be further clarified, it might be helpful for setting up a more individualized exercise and lifestyle modification program for women with PCOS in the future. In the current study, we aimed to investigate the role of the myostatin level and its relationship with the risk of abdominal obesity, androgen and follistatin levels in women with PCOS.
Materials and Methods

Subjects and data collection
Two hundred thirty-nine women with PCOS and a chief complaint of irregular menstrual cycles and/or clinical hyperandrogenism were recruited from the reproductive endocrinology clinic; none of the women had been prescribed any medications before enrollment. In addition, 38 healthy volunteers with regular ovulatory cycles (mean cycle length, 25 -32 days) and without any signs of clinical or biochemical hyperandrogenism were enrolled as the control group. The study protocol was approved by the Research Ethics Committee of the National Taiwan University Hospital. Written informed consent was obtained from all of the subjects before participation in the study. The inclusion and exclusion criteria for the enrollment of the subjects have been described in detail previously (Chen et al., 2006 (Chen et al., , 2009 . Briefly, the diagnosis of PCOS was based on the Rotterdam criteria, in which at least two of the following three criteria were met: (1) oligomenorrhea (,8 spontaneous menstrual cycles per year at least 3 years before enrollment) or amenorrhea; (2) biochemical hyperandrogenemia (serum total testosterone level .0.77 ng/ml) and (3) polycystic ovaries (.12 follicles [2-9 mm in size] per ovary by transvaginal ultrasonography or an ovarian volume .10 ml per ovary by transabdominal ultrasonography with a distended bladder for virginal women).
All of the study and control subjects were enrolled after excluding other endocrine, organic and systemic abnormalities, such as hyperprolactinemia, thyroid dysfunction, Cushing's syndrome, congenital adrenal hyperplasia, an adrenal tumor, an ovarian tumor, autoimmune disease, malignancy, central nervous system disease, current or previous use of oral contraceptives within 6 months of enrollment or the use of medications known to affect the hypothalamic -pituitary-ovarian axis (anti-androgens, ovulation induction agents, anti-diabetic medications, anti-obesity medications or glucocorticoids). None of the subjects were athletes or bodybuilders, and none of the subjects consumed alcoholic beverages or smoked cigarettes on a regular basis.
Overnight fasting blood samples were collected from PCOS subjects with amenorrhea exceeding 3 months without hormone-induced withdrawal bleeding, and in the early follicular phase from those women with PCOS who ovulated spontaneously and control subjects. The process for blood sampling and collecting for women with PCOS and control subjects has been described in detail previously (Chen et al., 2006 (Chen et al., , 2009 . Blood was processed within 30 min of collection. Blood glucose and insulin were determined on the day of sampling. The remaining serum and plasma were frozen at 2708C until assayed. The chosen cut-off value for waist circumference at 80 cm is based on the modified criteria of metabolic syndrome from the National Cholesterol Education Program-Adult Treatment Panel III, used for assessing abdominal obesity in Asian women (Tan et al., 2004) . The other cut-off value we used in the present study to define abdominal obesity was 0.8 for the waist-to-hip ratio, according to previous studies (Zaadstra et al., 1993; Chen et al., 2011) . Obesity was defined as a BMI ≥25 kg/m 2 , based on the guidelines for the adult Asian population (WHO, 2004) .
Laboratory assays
The concentration of plasma glucose was measured with an autoanalyzer (Toshiba TBA-120 FR; Toshiba, Tokyo, Japan). Serum insulin levels were determined by a microparticle enzyme immunoassay using an AxSYM system (Abbott Laboratories, Dainabot Co., Tokyo, Japan). Plasma follistatin levels were determined by an enzyme-linked immunosorbent assay (R&D Systems, Minneapolis, MN, USA). Plasma myostatin levels were determined by a competitive enzyme immunoassay technique (Immunodiagnostik AG, Bensheim, Germany). Serum follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol and progesterone were measured by indirect chemiluminescence (Vitros Eci; Ortho-Clinical Diagnostics, Rochester, NY, USA). Serum sex hormone binding globulin (SHBG) was measured by electrochemiluminescence (Elecsys 2010; Roche Diagnostics, USA). Serum total testosterone and DHEA-S were measured by radioimmunoassay (RIA; Diagnostic Systems Laboratories, Webster, TX, USA). The homeostasis model assessment (HOMA) and free androgen index (FAI) were applied to estimate the degree of IR and bioavailable testosterone, respectively. HOMA-IR and FAI were calculated as described previously (Chen et al., 2007) . The intra-and inter-assay coefficients of variation of the aforementioned assays were all ,10%.
Statistical analysis
The numerical data are presented as the mean + SD, unless indicated otherwise. The non-parametric analysis with Mann-Whitney U test was used for comparison of all variables between non-obese women with and without PCOS, and between non-obese and obese women with PCOS. The Shapiro-Wilk W test was used to identify whether or not variables were normally distributed. Log transformation was used for variables with significant deviation from a normal distribution before regression analysis. Univariate regression analyses were applied to assess the association between myostatin and the presence of PCOS, follistatin levels, anthropometric measures and hormonal profiles. Forward stepwise multivariate linear regression analyses were performed using myostatin as a dependent variable, and all the explanatory variables including age, the presence of PCOS, anthropometric measures, follistatin and androgen levels, metabolic and hormonal factors as the independent variables, as indicated. The probability of F entering the model was chosen as 0.05 and, of removal from the model, it was chosen as 0.10. The Kruskall-Wallis test was used to compare the differences in variables between the three myostatin tertiles. The risk of abdominal obesity in association with the myostatin tertiles in women with PCOS was compared using the two-sided Cochran-Armitage trend test and proportional logistic regression analyses for further multiple variables adjustment, when appropriate.
For all analyses, a P , 0.05 was considered statistically significant. All of the statistical analyses were performed using the PC version of the Statistical Analysis System (SAS, version 9.1; SAS Institute, Inc., Cary, NC, USA).
Results
The baseline characteristics and demographic data of the study and control subjects are shown in Table I . Among the 239 women with PCOS enrolled in this study, 135 (56.4%) were non-obese with a BMI ,25 kg/m 2 . The myostatin levels were statistically significantly higher in women with PCOS than those without PCOS (16.6 + 15.6 and 14.2 + 9.7, P ¼ 0.025), but not significantly different if only non-obese women with and without PCOS were considered (Table I ). In comparison with the non-obese women without PCOS, the fasting insulin, HOMA-IR, total testosterone, DHEAS and FAI levels were significantly higher in non-obese women with PCOS.
The age, BMI, waist circumference and follistatin showed no significant difference between non-obese women with and without PCOS. The obese women with PCOS had a higher BMI, waist circumference, fasting glucose, insulin, HOMA-IR and testosterone levels, but lower DHEAS and SHBG levels than non-obese women with PCOS, as expected. The follistatin and myostatin levels showed no significant differences between obese and non-obese women with PCOS (Table I) . With univariate regression analyses as shown in Table II , the myostatin level was significantly related to the presence of PCOS, waist circumference, BMI, total testosterone and FAI levels, but negatively related to the circulating SHBG, follistatin and DHEAS levels in all subjects. The myostatin level was still significantly related to the presence of PCOS (b ¼ 0.341, P ¼ 0.0003) after further adjustment for the BMI, total testosterone, DHEAS and follistatin levels by using multivariate regression analysis. Using stepwise multivariate linear regression analysis, only the presence of PCOS, total testosterone, DHEAS and follistatin were left significantly related to myostatin levels in the final model after the stepwise introduction of the presence of PCOS, age, BMI, waist circumference, fasting glucose, fasting insulin, HOMA-IR, FSH, LH, E2, total testosterone, SHBG, FAI, DHEAS and follistatin as independent variables (Table II) .
As expected, the myostatin levels in women with PCOS were positively associated with the obesity-related variables as BMI, waist circumference and fasting glucose levels as shown in Table III . For women with PCOS, the myostatin levels still inversely correlated with the DHEAS and follistatin levels, but were not significantly related to the total testosterone level in univariate regression analyses. However, by using stepwise multivariate linear regression analysis, only total testosterone, DHEAS and follistatin were left significantly related to myostatin levels in the final model after the stepwise introduction of age, BMI, waist circumference, fasting glucose, fasting insulin, HOMA-IR, FSH, LH, E2, total testosterone, SHBG, FAI, DHEAS and follistatin as independent variables in women with PCOS (Table III) . The relationship between myostatin and total testosterone was not significant without adding DHEAS as one of the independent variables in the models.
As shown in Table IV , women with PCOS who had the highest tertile of myostatin level had the highest risk of abdominal obesity (OR: 1.98, 95% CI: 1.06 -3.73, for a waist circumference cut-off of 80 cm; OR: 6.11, 95% CI: 2.87-13.02, for waist-to-hip ratio cut-off of 0.8). The risk of abdominal obesity tended to be higher among women with PCOS with a higher myostatin level. further adjustment of follistatin levels, waist circumference and fasting glucose and SHBG levels by multivariate linear regression analysis. The waist circumference (b ¼ 0.362, P ¼ 0.015) was still positively related to the myostatin level after adjustment for the DHEAS and follistatin levels in women with PCOS. The interaction terms between variables were all checked and not significant in the linear regression models.
Discussion
The present study showed that the myostatin level was significantly higher in women with PCOS than those without PCOS, but was not significantly different between non-obese women with and without PCOS after considering the effect of obesity. The myostatin level was significantly associated with the presence of PCOS after adjusting all the potential confounding variables including androgens and follistatin levels in all women. Since a previous study reported a correlation between increased body weight and increased muscle mass (Forbes, 1999 ), the increase in myostatin level associated with the presence of PCOS observed here might be due to the higher prevalence of obesity and hence increased lean mass in women with PCOS (Carmina et al., 2009) . The myostatin level is positively related to abdominal obesity, as represented by increased waist circumference and waist-to-hip ratio, but negatively associated with the concentration of circulating DHEAS and follistatin level in women with PCOS. The relationship between myostatin and abdominal obesity still persisted after further adjustment for the levels of androgen and follistatin in women with PCOS. Such findings in women with PCOS have never been reported before.
Myostatin is a negative regulator of muscle mass and strength in humans and animals (McPherron and Lee, 1997; Han et al., 2011) . Myostatin can affect metabolism through its influence on skeletal muscle, lean body mass, and also through other metabolically active tissues, such as liver and adipose tissues (Allen et al., 2008 (Allen et al., , 2011 . Obesity is associated with increased myostatin expression in humans and animals. Myostatin mRNA is increased in adipose and skeletal muscle in genetically obese mice, but decreased during weight loss (Allen et al., 2008) . Myostatin levels have also been reported to be higher in the circulation and muscle biopsies from obese than from non-obese women (Hittel et al., 2009 ), but decreased after weight loss by biliopancreatic diversion (Milan et al., 2004) or gastric bypass surgery (Park et al., 2006) in obese subjects. Such a relationship between the myostatin level and obesity was also confirmed in the current study, in that we found the level of myostatin was positively related to the BMI and waist circumference in women with PCOS.
Currently, there is increasing evidence that suggests the inhibition of myostatin through gene disruption (Guo et al., 2009; Wilkes et al., 2009; Burgess et al., 2011) , transgenic expression of myostatin antagonist as it's propeptide (Suzuki et al., 2008) or follistatin (Haidet et al., 2008; Nakatani et al., 2011) or direct administration of an antimyostatin antibody (Bernardo et al., 2010) , can significantly and attenuate the progression of obesity, IR and diabetes in animal studies. These studies further support the strong relationship between myostatin and obesity, and raise the possibility that strategies that can modulate the concentration or function of myostatin would be a novel therapeutic option to decrease adipocyte size, prevent obesity and heptatic steatosis, and improve glucose tolerance in obese human. Therefore, investigating the potential factors that affect the levels of myostatin might also help to control the obesity and IR and improve ovulatory dysfunction in women with PCOS in the future.
Androgens, such as testosterone and DHEA/DHEAS, alone or in combination with exercise, have been shown to increase muscle mass and strength in young and aging men (Bhasin et al., 1996; Bhasin et al., 2005) , and elderly women (Kenny et al., 2010) . However, little is known about the role of androgen on muscle metabolism in young women. In this study, we found that the DHEAS level was negatively, while the testosterone level was positively, related to the myostatin level in young women with PCOS. The DHEAS level, unlike the testosterone level, is comparable in men and women, and has been reported to be even higher in women than men of a similar age, BMI, and insulin level (Jakubowicz et al., 1995) . Previous studies reported the opposing effect of DHEAS and testosterone on IR and abdominal obesity in women with PCOS (Buffington et al., 1991; Brennan et al., 2009; Chen et al., 2011) . Unlike testosterone, DHEAS have been reported to have several beneficial effects on metabolism, including anti-diabetic, anti-obesity (Williams et al., 1993) and anti-atherogenic effects (Ebeling and Koivisto, 1994; Wang et al., 2011) . In the present study, the DHEAS and testosterone levels were also shown to have similar differential effects on abdominal obesity and myostatin levels in women with PCOS.
However, previous studies regarding the relationship between myostatin and androgens were limited and conflicting. The gender difference of the myostatin level has been noted in mice (McMahon et al., 2003) , but not in humans (Lakshman et al., 2009 ). In addition, it has been reported that testosterone treatment may suppress myostatin expression directly or indirectly through an increase in potent myostatin inhibitors, such as follistatin and myostatin propeptide expression in mice studies (Mendler et al., 2007; Diel et al., 2010 ). However, the myostatin level was noted to be increased by shortterm testosterone supplementation in men (Lakshman et al., 2009 ). The present study cannot explain the conflicting results from the above studies, but we did find that the myostatin level became significantly associated with the total testosterone level after adjusting the concurrent high DHEAS levels in women with PCOS by using multivariate regression models, suggesting that the interaction between testosterone and DHEAS should be considered when investigating the effect of androgen on myostatin. However, further studies are necessary to elucidate such conflicting effects of androgens on myostatin.
In conclusion, the present study showed that the myostatin level was inversely related to circulating DHEAS and follistatin levels in women with PCOS. Myostatin levels were positively associated with an increased risk of abdominal obesity in women with PCOS; such a relationship persisted after further adjustment for follistatin, DHEAS and total testosterone levels in women with PCOS. Therefore, the finding of the present study might imply a potential regulatory role of androgen and follistatin in the metabolism of skeletal muscle in women with PCOS.
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